Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC.

•Olaratumab (IMC-3G3) is a fully human anti-PDGFR monoclonal antibody.•Olaratumab plus carboplatin-paclitaxel does not prolong PFS or OS in NSCLC.•PDGFR expression is rare in NSCLC tumor cells but common in NSCLC stroma.•The addition of olaratumab to chemotherapy is well tolerated.